India Enters The 'Pay-For-Delay' Fray
India's competition authority, the Competition Commission of India (CCI), has begun scrutinizing and investigating pharmaceutical patent settlement agreements between brand and generic firms for potential anti-competitive effects.[1] It has been reported...To view the full article, register now.
Already a subscriber? Click here to view full article